Oxford Cancer Analytics (OXcan), an Oxford-based medtech company, has raised £9m in a Series A round led by We Venture Capital and Cross-Border Impact Ventures. Founded by Dr. Peter Jianrui Liu and Dr. Andreas Halner, OXcan is developing advanced proteomics and AI-powered liquid biopsy blood tests to enable early detection of lung cancer, the leading cause of cancer mortality worldwide.
The funding will support OXcan's global deployment of its minimally invasive, cost-effective blood tests, leveraging a diverse biobank and partnerships with over 20 healthcare centres across three continents. OXcan's tests aim to improve patient outcomes by detecting cancer at earlier stages, enabling curative treatments and reducing healthcare burdens.
